eBulletin Newsletter

NCCN Flash Updates: NCCN Guidelines Updated for Uterine Neoplasms

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium^®) for Uterine Neoplasms. These NCCN Guidelines^® are currently available as Version 3.2024.

Link directly to the Updates section of the NCCN Guidelines: Uterine Neoplasms

Endometrial Carcinoma

ENDO-D 1 of 4 Systemic Therapy for Endometrial Carcinoma

• Primary or Adjuvant Therapy (Stage I-IV)
  • Systemic Therapy; Preferred regimens: Carboplatin/paclitaxel/durvalumab (for stage III–IV dMMR tumors only) added as category 1 option.
  • Footnote "f" is new: For Stage III with measurable disease post surgery and stage IV with or without measurable disease.

ENDO-D 2 of 4

• Recurrent Disease
  • First-line Therapy for Recurrent Disease; Preferred regimens: Carboplatin/paclitaxel/durvalumab (for dMMR tumors only) added as category 1 option.
  • Footnote m is new: For adult patients with recurrent endometrial carcinoma with or without measurable disease.
  • Footnotes removed:
    • For stage IIIA, IIIB, or IIIC1 with measurable disease, stage IIIC1 with carcinosarcoma, clear-cell, serous, or mixed histology regardless of the presence of measurable disease; and stage IIIC2 or stage IV regardless of the presence of measurable disease.
    • For stage III or IVA with measurable disease or stage IVB with or without measurable disease

ENDO-D 4 of 4

• Reference 10 is new: Westin SN, Moore K, Chon HS, et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The Phase III DUO-E trial. J Clin Oncol. 2023;42:283-299.

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients^®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium^®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Third Party Content: The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content site: private.filesanywhere.com/fs/v.aspx?v=8a6d65cfa19ea4bda0a3&C=6241. Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works. 

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.